5-(甲基氨基)-2-氰基吡啶 | 1256806-82-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-(甲基氨基)-2-氰基吡啶
• 英文名称: 5-(Methylamino)picolinonitrile
• 英文别名: 5-(methylamino)pyridine-2-carbonitrile
• CAS: 1256806-82-2
• 化学式: C₇H₇N₃
• 分子量: 133.15
• InChiKey: WMBBYSJOTOXRPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  48.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P280
• 危险性描述：
  H302,H312,H332

文献信息

• [EN] NOVEL TRICYCLIC COMPOUNDS AS BCR-ABL INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS TRICYCLIQUES UTILISÉS COMME INHIBITEURS DE BCR-ABL
  申请人：ASCENTAGE PHARMA SUZHOU CO LTD

  公开号：WO2021018195A1

  公开（公告）日：2021-02-04

  The present disclosure provides compounds represented by Formula (I), or an enantiomer or diastereomer, or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, L, Ar, R1, R2, R3 R4, R5, R6, m, and p are defined herein. Compounds of Formula (I) are BCR-ABL inhibitors. BCR-ABL inhibitors are useful for the treatment of cancer and other diseases.

  本公开提供由式(I)表示的化合物，或其对映体或二对映体，或其药用可接受的盐，其中X、Y、Z、L、Ar、R1、R2、R3、R4、R5、R6、m和p在此定义。式(I)的化合物是BCR-ABL抑制剂。BCR-ABL抑制剂对于治疗癌症和其他疾病非常有用。
• [EN] NOVEL PqsR INVERSE AGONISTS<br/>[FR] NOUVEAUX AGONISTES INVERSES DE PQSR
  申请人：HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH

  公开号：WO2021136805A1

  公开（公告）日：2021-07-08

  The present invention relates to a compound according to general formula (I), which acts as an inverse agonist of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS), sometimes also referred to as MvfR); to a pharmaceutical composition containing one or more of the compound(s) of the invention: to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.

  本发明涉及一种化合物，其通式为（I），作为PqsR的反向激动剂（目前已知的Pseudomonas Quinolone Signal（PQS）受体，有时也称为MvfR）；一种含有该化合物的药物组合物；至少包含本发明化合物之一和至少一种其他活性药物成分的组合制剂；以及该化合物的用途，包括作为药物的用途，例如用于治疗或预防细菌感染，特别是铜绿假单胞菌或伯克霍尔德氏菌感染。
• 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof
  申请人：Zhang Nan

  公开号：US20090270363A1

  公开（公告）日：2009-10-29

  The present invention discloses fused bicyclic 2-aryl- or 2-heteroarylthiazolyl compounds and their pharmaceutically acceptable salts and esters thereof, which are useful for inhibiting the growth of cancerous cells, inhibiting human breast carcinoma tumor growth in particular and to treat diseases or disorders associated with securin, including elevated securin levels.

  本发明公开了融合的双环2-芳基-或2-杂环基硫唑基化合物及其药学上可接受的盐和酯，其对抑制癌细胞生长、特别是对抑制人类乳腺癌肿瘤生长以及治疗与分离素有关的疾病或疾病相关障碍，包括升高的分离素水平具有用处。
• Amide Compound
  申请人：Matsumoto Takahiro

  公开号：US20080312226A1

  公开（公告）日：2008-12-18

  There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I 0 ): R 1 —C—R 2 —R 3 —R 4 (I 0 ) wherein Z is oxygen or sulfur; R 1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R 1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R 2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R 3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, —CO—, etc.; and R 4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

  提供了一种FAAH抑制剂和预防或治疗脑血管疾病或睡眠障碍的药物，其中预防或治疗剂包括化合物(I0)的一种：R1-C-R2-R3-R4(I0)，其中Z为氧或硫；R1为芳基，可以被取代，或者是可以被取代的杂环基；R1a为氢原子，可以被取代的碳氢基，羟基等；R2为可以被取代的哌啶-1,4-二基，或者可以被取代的哌嗪-1,4-二基；R3为从具有1到3个氮、氧和硫杂原子的5元芳香杂环基中消除两个氢原子形成的基团，可以进一步被取代，-CO-等；R4为可以被取代的碳氢基或者可以被取代的杂环基；或其盐。
• QUINAZOLINE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160250215A1

  公开（公告）日：2016-09-01

  Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

  本文描述了式（I）的化合物及其互变异构体和药物盐，含有这种化合物的组合物和配方，以及使用和制备这种化合物的方法。